Publication

[iScience] Researchers developed a multifocal HCC model to test immunotherapies by introducing c-myc using hydrodynamic gene transfer along with CRISPR-Cas9-mediated disruption of p53 in mouse hepatocytes.

[Heliyon] Investigators showed that mesenchymal stem cell-derived exosomes as an anti-inflammatory agent in combination with metformin could increase the therapeutic efficacy of metformin without needing to change metformin doses by decreasing inflammatory cytokines production, including IL-1, IL-6, and TNF-α and apoptosis in HepG2 cells.

[Acta Biochimica Et Biophysica Sinica] To identify the mesenchymal stem cells that are most suitable for hepatic differentiation and the treatment of liver failure, investigators used a three-phase induction process in which human adipose-derived stem cells and umbilical cord mesenchymal stem cells were induced to differentiate towards hepatocyte-like cells in vitro.

[Pathology Research And Practice] Researchers suggested absent in melanoma 2 (AIM2) played an inhibitory role in regulating the growth and metastasis of HCC, which supported the notion that AIM2 could serve as a potential therapeutic target for HCC.

[Proceedings Of The National Academy Of Sciences Of The United States Of America] Scientists assessed the intrinsic fitness of BA.5 and prior SARS-CoV-2 variants in adult stem cell-derived human respiratory organoids, which simulated the human upper and lower respiratory epithelium.

[Nature Communications] Using patient-derived organoid cultures from different bladder cancer stages and grades, integrative analysis of drug response profiles with matched genomic analyses were carried out to determine enrichment thresholds for candidate markers of therapy response and resistance.